aTyr Pharma, Inc. filed a current report on November 6, 2026, disclosing the submission of a prospectus supplement to the SEC covering the potential at-the-market sale of common stock with an aggregate offering price of up to $79,994,251.

Key Highlights

  • Offering cap: aTyr Pharma may offer and sell common stock with an aggregate offering price of up to $79,994,251.
  • Sales agreement: The offering is conducted under the Open Market Sale Agreement, originally dated April 22, 2022 and amended December 23, 2024, with Jefferies LLC as the sales agent.
  • Shelf registration: The prospectus supplement was filed under a Form S-3 shelf registration (File No. 333-289360), initially filed August 7, 2025 and declared effective August 18, 2025.
  • Exchange listing: aTyr Pharma common stock, par value $0.001 per share, trades on NASDAQ:ATYR.
  • Legal opinion: A legality opinion from Cooley LLP (Exhibit 5.1) was filed covering the $79,994,251 of shares issuable under the Sales Agreement.
  • Signed by: The report was signed by Brandon Yaras, Chief Financial Officer, on November 6, 2026.

aTyr Pharma Files Prospectus Supplement for At-the-Market Common Stock Sales

According to the filing, aTyr Pharma, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121, disclosed on November 6, 2026 that it had filed a prospectus supplement with the SEC. The supplement relates to the potential sale of the company's common stock, par value $0.001 per share, with an aggregate offering price of up to $79,994,251.

The filing states that the sales are to be conducted from time to time under the company's Open Market Sale Agreement, which was originally entered into on April 22, 2022 and subsequently amended on December 23, 2024, with Jefferies LLC serving as the counterparty. This type of arrangement, commonly called an at-the-market program, allows an issuer to sell shares into the existing trading market at prevailing prices rather than through a fixed-price underwritten offering.

The prospectus supplement was filed under aTyr Pharma's shelf registration statement on Form S-3 (File No. 333-289360), which the company disclosed was initially filed with the SEC on August 7, 2025 and declared effective on August 18, 2025. The company also filed, as Exhibit 5.1, a legal opinion from Cooley LLP addressing the legality of the shares of common stock issuable under the Sales Agreement and covered by the prospectus supplement, along with Cooley LLP's consent included within that exhibit.

What Was Disclosed

aTyr Pharma reported the filing of a prospectus supplement on November 6, 2026, permitting at-the-market sales of common stock up to $79,994,251 in aggregate offering price, conducted through Jefferies LLC under an existing sales agreement and a shelf registration statement declared effective August 18, 2025.